Conferences - Results from #120

ASCO GU 2021: PROSPER Subgroup Analysis by Age and Region: Overall Survival and Safety in Men With Nonmetastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy Plus Enzalutamide February 16, 2021

ASCO GU 2021: Molecular Landscape of Non-Muscle-Invasive Bladder Cancer and Subcellular Risk Factors for Progression February 16, 2021

ASCO GU 2021: Efficacy of Chemohyperthermia in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Fail BCG Therapy February 16, 2021

ASCO GU 2021: Heterogeneity in Nectin-4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin February 16, 2021

ASCO GU 2021: Best of the Journals: Renal Cell Carcinoma – Surgery February 16, 2021

ASCO GU 2021: Best of the Journals: Renal Cell Carcinoma – Pathology February 16, 2021

ASCO GU 2021: TRISST: Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results from a Randomized, Phase III, Factorial Trial February 16, 2021

ASCO GU 2021: Overall Survival and Metastasis-Free Survival by Depth of PSA Decline in the Phase III PROSPER Trial of Men With nmCRPC Treated with Enzalutamide February 14, 2021

ASCO GU 2021: Real-World Clinical Outcomes Study of Sequential Novel Antihormonal Therapy (NAH) or Ra-223 Treatment of mCRPC That Progressed After First-Line NAH February 14, 2021

ASCO GU 2021: Phase II/III Clinical Results of IL-15RαFc Superagonist N-803 With BCG in BCG-Unresponsive NMIBC Carcinoma In Situ Patients February 14, 2021

ASCO GU 2021: Characterization of FOXF1 as a Novel Regulator of Nodal Metastasis in Bladder Cancer February 14, 2021

ASCO GU 2021: Best of Journals: Renal Cell Carcinoma – Medical Oncology February 14, 2021

ASCO GU 2021: Outcomes of First-Line Immuno-Oncology Combination Therapies in Metastatic Renal Cell Carcinoma: Results from the International mRCC Database Consortium February 14, 2021

ASCO GU 2021: Stereotactic Radiotherapy and Pembrolizumab for Oligometastatic Renal Tumors: The RAPPORT Trial February 14, 2021

ASCO GU 2021: Angiogenic and T-Effector Subgroups Identified by Gene Expression Profiling and Propensity for PBRM1 and BAP1 Alterations in Clear Cell Renal Cell Carcinoma February 14, 2021

ASCO GU 2021: Avelumab First-Line Maintenance Plus Best Supportive Care vs Best Supportive Care Alone For Advanced Urothelial Carcinoma: JAVELIN Bladder 100 Subgroup Analysis Based On Duration And Cycles Of First-Line Chemotherapy February 14, 2021

ASCO GU 2021: TIVO-3: Tivozanib in Patients with Advanced Renal Cell Carcinoma Who Have Progressed After Treatment with Axitinib February 14, 2021

ASCO GU 2021: NAXIVA: A Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumor Thrombus in Clear Cell Renal Cell Cancer with Venous Invasion February 14, 2021

ASCO GU 2021: Sarcomatoid Versus Clear Cell RCC: A Comparative Comprehensive Genomic Profiling Study February 14, 2021

ASCO GU 2021: Illustration of Temporal Evolution in Patients with mRCC Using Both ctDNA and Tissue-Based Genomic Data February 14, 2021

Page 7 of 392